Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab.
Vicky MakkerMatthew H TaylorAna OakninAntonio Casado HerraezRobert OrlowskiLea DuttaMin RenMelissa ZaleDavid M O'MalleyPublished in: The oncologist (2021)
Lenvatinib plus pembrolizumab has shown efficacy in the treatment of patients with advanced endometrial carcinoma (that is, not microsatellite instability-high or mismatch repair deficient) following at least one prior systemic therapy in any setting. Patients may experience toxicity associated with this combination, including adverse reactions of hypertension, fatigue, nausea/vomiting, diarrhea, decreased appetite/weight loss, hypothyroidism, palmar-plantar erythrodysesthesia syndrome, musculoskeletal pain, stomatitis, and proteinuria. These adverse reactions may be managed with a combination of concomitant supportive care medications and judicious lenvatinib dose modifications. This article provides context and guidance for the recognition and management of adverse reactions in patients receiving lenvatinib plus pembrolizumab.
Keyphrases
- weight loss
- advanced non small cell lung cancer
- end stage renal disease
- newly diagnosed
- blood pressure
- healthcare
- bariatric surgery
- ejection fraction
- chronic kidney disease
- chronic pain
- pain management
- palliative care
- adverse drug
- endometrial cancer
- oxidative stress
- quality improvement
- neuropathic pain
- replacement therapy
- spinal cord injury
- depressive symptoms
- type diabetes
- adipose tissue
- body weight
- mesenchymal stem cells
- skeletal muscle
- combination therapy
- bone marrow
- genetic diversity
- weight gain
- smoking cessation
- drug induced